Investment Thesis
We believe breakthrough science only matters when it reaches people. We back founders solving problems that prevent therapies from reaching patients, including manufacturing bottlenecks, slow clinical development, and inefficient data use.
Stage Focus
Early-stage to growth-stage
Preferred startup development maturity for initial funding deployment.
Sectors & Themes
Breakthrough life sciences companies, including new therapies, scalable manufacturing platforms, and tools for faster clinical development and data analysis
Core thematic spaces, technologies, and target market segments of interest.
Check Size Range
€20,865,000 - €92,000,000
Standard financial allocation per investment round.
Outreach & Dossier Intelligence
Direct Verification Contact Email Pattern
Thesis Dossier Analysis Scorecard
Our agent analyzer scanned portfolio holdings and verified absolute match parameters...
Investment Team (17)
A
Alan Barge
Venture Partner
C
Carol Lynch
Advisor
C
Christopher Spray
Advisor
C
Colin Freund
Partner
I
Igor Linshits
Founder
I
Iskender Dirik
Partner
J
Jakub Czarnecki
Financial Controller
J
John Campbell
EIR
J
Jonathan Hay
Partner
L
Larry Illg
Advisor
M
Matt Symes
Investor
M
Miguel Forte
Advisor
M
Muz Mansuri
Advisor
O
Oliver Hemmings
Analyst
R
Rosie Barnett
Principal
S
Sarah Shackelton
Advisor
Z
Ziaf Rehman
Associate